Cargando…
Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
Therapeutic drug monitoring may be useful in tuberculosis management, but programmatic implementation is understudied. We performed a retrospective cohort study to determine prevalence of lower than expected levels of isoniazid, rifampin, ethambutol, and pyrazinamide measured at time of estimated pe...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3294393/ https://www.ncbi.nlm.nih.gov/pubmed/20875279 http://dx.doi.org/10.3201/eid1610.100374 |
_version_ | 1782225489577902080 |
---|---|
author | Heysell, Scott K. Moore, Jane L. Keller, Suzanne J. Houpt, Eric R. |
author_facet | Heysell, Scott K. Moore, Jane L. Keller, Suzanne J. Houpt, Eric R. |
author_sort | Heysell, Scott K. |
collection | PubMed |
description | Therapeutic drug monitoring may be useful in tuberculosis management, but programmatic implementation is understudied. We performed a retrospective cohort study to determine prevalence of lower than expected levels of isoniazid, rifampin, ethambutol, and pyrazinamide measured at time of estimated peak serum concentration. Patients were tested for serum concentration at 2 hours after medication administration. When patients were tested, 22 had concentrations lower than expected range for rifampin, 23 of 39 patients had low levels of isoniazid, and 8 of 26 patients had low levels of ethambutol; all 20 patients tested for pyrazinamide were within expected range. Over 26 months, 42 patients met criteria for slow response. Diabetes was associated with slow response (p<0.001), and persons with diabetes were more likely than persons without diabetes to have low rifampin levels (p = 0.03). Dosage adjustment of rifampin was more likely to elevate serum concentration to the target range than adjustment of isoniazid given in daily doses (p = 0.01). |
format | Online Article Text |
id | pubmed-3294393 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-32943932012-03-08 Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA Heysell, Scott K. Moore, Jane L. Keller, Suzanne J. Houpt, Eric R. Emerg Infect Dis Research Therapeutic drug monitoring may be useful in tuberculosis management, but programmatic implementation is understudied. We performed a retrospective cohort study to determine prevalence of lower than expected levels of isoniazid, rifampin, ethambutol, and pyrazinamide measured at time of estimated peak serum concentration. Patients were tested for serum concentration at 2 hours after medication administration. When patients were tested, 22 had concentrations lower than expected range for rifampin, 23 of 39 patients had low levels of isoniazid, and 8 of 26 patients had low levels of ethambutol; all 20 patients tested for pyrazinamide were within expected range. Over 26 months, 42 patients met criteria for slow response. Diabetes was associated with slow response (p<0.001), and persons with diabetes were more likely than persons without diabetes to have low rifampin levels (p = 0.03). Dosage adjustment of rifampin was more likely to elevate serum concentration to the target range than adjustment of isoniazid given in daily doses (p = 0.01). Centers for Disease Control and Prevention 2010-10 /pmc/articles/PMC3294393/ /pubmed/20875279 http://dx.doi.org/10.3201/eid1610.100374 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Research Heysell, Scott K. Moore, Jane L. Keller, Suzanne J. Houpt, Eric R. Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA |
title | Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA |
title_full | Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA |
title_fullStr | Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA |
title_full_unstemmed | Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA |
title_short | Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA |
title_sort | therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, virginia, usa |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3294393/ https://www.ncbi.nlm.nih.gov/pubmed/20875279 http://dx.doi.org/10.3201/eid1610.100374 |
work_keys_str_mv | AT heysellscottk therapeuticdrugmonitoringforslowresponsetotuberculosistreatmentinastatecontrolprogramvirginiausa AT moorejanel therapeuticdrugmonitoringforslowresponsetotuberculosistreatmentinastatecontrolprogramvirginiausa AT kellersuzannej therapeuticdrugmonitoringforslowresponsetotuberculosistreatmentinastatecontrolprogramvirginiausa AT houptericr therapeuticdrugmonitoringforslowresponsetotuberculosistreatmentinastatecontrolprogramvirginiausa |